Clinical Trials
9 trialsNCT01875237 2019-07-16
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00801931 2019-03-27
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
Columbia University
Phase 1/2 Terminated
NCT00626626 2018-04-25
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT00698685 2017-03-31
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
University of Arizona
Phase 2 Terminated
NCT01518153 2016-03-17
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00943293 2014-03-17
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
University of Chicago
Phase 1 Terminated
NCT00818961 2013-12-18
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Northside Hospital, Inc.
Phase 2 Terminated
NCT00453193 2012-08-07
Alemtuzumab and Pentostatin In T-cell Neoplasms
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00505921 2011-11-16
Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated